← All trials
NCT03341156
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2018
- Primary completion
- Nov 1, 2019
- Completion date
- Nov 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PittsburghLead sponsor
- CSL BehringCollaborator
- University of PittsburghSponsor investigator
- University of PittsburghOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- University of MarylandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.